Title
Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender women
Date Issued
01 February 2019
Access level
open access
Resource Type
journal article
Author(s)
Cranston R.D.
Carballo-Diéguez A.
Gundacker H.
Richardson B.A.
Giguere R.
Dolezal C.
Siegel A.
KunjaraNaAyudhya R.P.
Gomez K.
Piper J.M.
McGowan I.
Publisher(s)
SAGE Publications Ltd
Abstract
Human papillomavirus (HPV) prevalence varies by population. This study investigated anal HPV type detection risk by country in a population of men who have sex with men (MSM) and transgender women (TW) at risk of HIV. Sexually active HIV-1-uninfected MSM and TW were enrolled at eight sites: four in the United States (US), two in Thailand, one in Peru, and one in South Africa. Baseline anal HPV swabs were collected, and DNA typing was performed. One hundred and ninety-five participants, 76 (42%) from the US, had a mean age of 30.9 years (range 18–64). In 182 participants with results available, anal HPV infection was common with 169 (93%) with ≥1 type, 132 (73%) with ≥1 nine-valent vaccine types, and 66 (36%) with HPV 16. Participants in the US had a higher prevalence of HPV 16 (56%, p = 0.004) and HPV 6 (69%, p < 0.001) compared to the other regions. Stimulant drug use was significantly associated with HPV 6 detection. Anal HPV is highly prevalent in this population of MSM and TW sampled from four countries, with HPV 16 the most commonly detected type. The nine-valent HPV vaccine has the potential to provide significant protection if given prior to exposure.
Start page
154
End page
162
Volume
30
Issue
2
Language
English
OCDE Knowledge area
Dermatología, Enfermedades venéreas
Scopus EID
2-s2.0-85060126538
PubMed ID
Source
International Journal of STD and AIDS
ISSN of the container
09564624
Sponsor(s)
We are grateful to the study participants for their participation and dedication. We thank the study team members at the research sites, the protocol management team, and the MTN leadership operations center for their contributions. We are grateful to Gilead Sciences who provided the FTC/TDF and CONRAD for providing RG-TFV. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the other institutions represented.
Sources of information: Directorio de Producción Científica Scopus